Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cost-effectiveness of polatuzumab vedotin + R-CHP versus R-CHOP in previously untreated diffuse large B-cell lymphoma in Japan
jRCT1031230035Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Trial of polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, prednisone and 1 more in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Incremental cost-effectiveness ratio (ICER) for Pola + R-CHP compared with R-CHOP. Started Apr 2023; status: completed.
02
Drugs
polatuzumab vedotinrituximabcyclophosphamidedoxorubicinprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT1031230035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031230035.